Clinical trials: Early Onset Alzheimer Disease
Alzheimer Disease
Early Onset Alzheimer's Disease Genomic Study
The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis.
- Trial name
- TGen (NCT03645993)
- Testing
- Genetic Testing
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Alzheimer Disease, Early Onset, MCI
The Interactive Physical and Cognitive Exercise System
This study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise.
- Conditions
- Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment
- Trial name
- iPACES™ (NCT03069391)
- Testing
- physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Union College, New York
Alzheimer Disease, Early Onset
Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia
Young-onset dementia (YOD) is a devastating condition, and it produces substantial psychosocial impacts on individual's functioning and family's care burden. Alzheimer's disease (AD) dementia is the most common type in YOD.
- Trial name
- NCT04042532
- Testing
- Theta-burst stimulation (TBS)
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease, Early Onset
The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology.
- Trial name
- EEG (NCT05989087)
- Testing
- CSF
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Görsev Yener, MD, PhD
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimer Disease, Early Onset
Eardream Data Collection in Colombia Supported by ADDF
Data collection based on this study will allow us to collect neurophysiological and cognitive data collected from in-ear EEG recordings of the Autosomal dominant alzheimer's disease population in Colombia
- Trial name
- NCT05570370
- Testing
- This is an observational study
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Swiss Federal Institute of Technology
Early Onset Alzheimer Disease
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
- Trial name
- NCT04002583
- Testing
- Computer assisted ambulatory electroencephalogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and…
- Conditions
- Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia, Non Pharmacological Intervention
- Trial name
- MUSENGAGE (NCT06688968)
- Testing
- neuropsychologist interview, questionnaire
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Down Syndrome (Trisomy 21), Neuropsychology
Neuropsychological Evaluation in Intellectual Disability (ENDI)
The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.
- Conditions
- Down Syndrome (Trisomy 21), Neuropsychology, Cognitive Aging, Alzheimer Disease
- Trial name
- ENDI (NCT07047963)
- Testing
- ENDI (Neuropsychological Evaluation in Intellectual Disability)
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Alzheimer Disease, Early Onset, Parkinson Disease
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal…
- Trial name
- NODAL (NCT06080659)
- Testing
- fMRI, CONFMEM
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Alzheimer Dementia, Presenile Alzheimer Dementia
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on…
- Conditions
- Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
- Trial name
- ISTIM-AD (NCT04289402)
- Testing
- Personalized tDCS
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hebrew SeniorLife
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Frailty, Cognitive Impairment
A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty
Cognitive frailty, characterized by the coexistence of physical frailty and cognitive impairment, is a robust indicator of cognitive decline.
- Conditions
- Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild
- Trial name
- NCT05754021
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Baylor College of Medicine
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer Disease, Early Onset
Efavirenz for Patients With Alzheimer's Disease
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early dementia due to Alzheimer's…
- Trial name
- EPAD (NCT03706885)
- Testing
- Sustiva Pill
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Western Reserve University
Mild Cognitive Impairment (MCI), Dementia
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective…
- Conditions
- Mild Cognitive Impairment (MCI), Dementia, Alzheimer Disease, Early Onset, Alzheimer Disease
- Trial name
- MuSt-MID (NCT06668610)
- Testing
- StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS, Cognitive treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Campania Luigi Vanvitelli